Rezultati pretrage - Matko Kalac

  • Prikaz rezultata 1 – 5 od 5
Detaljiziraj rezultate
  1. 1
    Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

    Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma od Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Ellen Neylon, Paul Johannet, Ying Wei, Jasmine Zain, Owen A. O’Connor

    Izdano 2013
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma

    Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma od Matko Kalac, Salvia Jain, Constantine S. Tam, Zhengrui Xiao, Francesca Montanari, Jennifer A. Kanakry, Bryan D. Huber, Mendel Goldfinger, Owen A. O’Connor, Enrica Marchi

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

    HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL od Matko Kalac, Luigi Scotto, Enrica Marchi, Jennifer E. Amengual, Venkatraman Seshan, Govind Bhagat, Netha Ulahannan, Violetta V. Leshchenko, Alexis M. Temkin, Samir Parekh, Benjamin Tycko, Owen A. O’Connor

    Izdano 2011
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

    A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma od Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine E. Atkins, Aishling M. Rada, Hye A. Kim, Codruța Chiuzan, Matko Kalac, Enrica Marchi, Lorenzo Falchi, Mark A. Francescone, Lawrence Schwartz, Serge Cremers, Owen A. O’Connor

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

    Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial od Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas, Jennifer E. Amengual, Changchun Deng, Matko Kalac, Lorenzo Falchi, Enrica Marchi, Ithamar Turenne, Renee Lichtenstein, Celeste Rojas, Mark Francescone, Lawrence H. Schwartz, Bin Cheng, Kerry J. Savage, Diego Villa, Michael Crump, Anca Prica, Vishal Kukreti, Serge Cremers, Joseph M. Connors, John Kuruvilla

    Izdano 2017
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: